PHELA is a herbal traditional medicine that is under development for use as an immune booster in immune compromised individuals. Therefore, the aim of this study was to determine PHELA's mechanism of action by observing for changes in cytokine profiles. Four groups of Sprague Dawley rats (n = 8) were treated daily and separately with normal-saline, cyclosporine-A, PHELA-only and PHELA+ cyclosporine-A. Thereafter, 4 animals from each group were sacrificed after 7 and 14 days of treatment. Serum Th1 cytokines (IL-2, IFN-γ and TNF-ά) and Th2 cytokines (IL-4 and IL-10) were measured by ELISA. The concentrations of Th1 cytokines in the PHELA-only treated group were similar to the control group on days 7 and 14. However, the Th1 cytokines were higher in the PHELA+cyclosporine-A treated group compared to cyclosporine-A group, and cyclosporine-A concentrations were similar in both groups. These results show that PHELA did not stimulate Th1 cytokines of a normal immune system but stimulated them when the immune system was suppressed by cyclosporine-A. In conclusion, PHELA is an immune-stimulant to a compromised immune system.
Specifically, the aim of this study was to determine the effect of PHELA on the immune system by observing for subclinical changes in Th 1 cytokines (IL-2, IFN-γ, TNF-α) that would enhance cell mediated immunity and Th 2 cytokines (IL-4 and IL-10) that would enhance the humoral response, with a hope that understanding the mechanism of action will help in designing immune booster therapy. 
METHODS

PHELA
Animal care
Ethical approval was obtained from the Animal Ethics Committee of the University of the Free State. Sprague-Dawley (SD) rats weighing 260 -400 g were used. Animals were kept and treated at the Animal House of the University of the Free State where they were cared for by qualified staff according to International animal care guidelines. They were fed on Standard rat chow and water ad libitum, and the cages were cleaned twice a week. During treatment, animals were inspected for skin lesions and other visible adverse events every day.
Experimental design
The animals were divided into six groups whereby four groups had 8 rats each while the fifth group had 12 rats and the sixth group 4 rats. The four groups were treated daily with either normal-saline orally (control), cyclosporine 2 mg/kg in olive oil, subcutaneously (Cys: negative control), PHELA 15.4 mg/kg orally (test-group-1), and PHELA+cyclosporine (PHELA+Cys: test-group-2). Thereafter, 4 animals from each group were sacrificed after 7 and 14 days of treatment. The fifth group was inoculated once intramuscularly (laterally on the thigh) with influenza vaccine 0.2 ml (positive control) after which 4 animals were sacrificed after 7, 14 and 21 days. The sixth was not treated with anything (untreated), hence, was used to determine the status of immune system at base line (i.e., in unmanipulated animals).
Surgical procedure and blood collection and analysis
Under ether anaesthesia, blood (8-10 ml) was drawn via cardiac puncture and immediately aliquoted into the appropriate testtubes. The rat was sacrificed by exsanguination whilst still under anaesthesia. Blood was collected for liver function tests and full blood count, PHELA concentration and cytokine analysis. Liver and renal functions tests and the full blood count were done by Pathcare Vetinary Laboratory (Bloemfontein, South Africa), while PHELA concentrations were measured by HPLC using a method developed in our laboratory and cyclosporine was analyzed by fluorescent Polarization Immuno-Assay (FPIA) using a Kit (cyclosporine assay for whole blood) according manufacturer's instruction (.Abbots Laboratories., Abbot Park, IL, USA). Serum cytokines, rat IL-2, IFN-γ, TNF-α, IL-4 and IL-10 were measured by ELISA on a UV-spectrophotometry with a microplate reader (HP, USA) and according to the manufacturer's instruction.
Data analysis
The response of cytokines to the treatment with different agents was evaluated by analysing the reponse pattern in the Th1 cytokines (IL-2, IFN-γ and TNF-α) and Th2 cytokines (IL-4 and IL-10) versus the respective controls. Data was analyzed by non-parametric methods using the GraphPad Instat statistical program. Accordingly, summary data were reported as median and range, and the MannWhitney Test was used for data comparison with the level of significance set at p < 0.05. Table 1 shows the changes in animals' weights, the liver and renal function tests over the treatment period. The change in weight was 0 -1.8% in the first week, 1 -5.5% in the second week, and 8.5% in the third week. This was within the expected range for age and all the changes in the different groups were similar to those of the control group. Also these changes in weight at 7 and 14 days did not warrant a change in drug dosage, while dosing was not applicable at 21 days after influenza vaccination because the vaccine was given once. Also, the liver function indicated by the ALT and ALK, and the renal function indicated by creatinine and urea, were normal. Table 2 and 3 illustrate the full blood count data. In Table 2 , there were no changes in the WBC on the three occasions. However, Table 3 shows that there was significant reduction in the platelet count in the cyclosporine group on day 7 and 14, and this was antagonized by PHELA in the PHELA + cyclosporine group.
Results
Physiological parameters
Cytokines profiles
The effects of the different agents on the Th1 and Th2 cytokines tended to be more pronounced at 7 days of therapy. Thereafter, the cytokine levels in most cases either returned to baseline or were similar to those in the control group, most probably owing to endognous immune adjustments. Figure 1 shows that the effect of Influenza vaccine on Th1 cytokines (IL-2, IFN-γ and TNF-α) and Th2 cytokines (IL-4 and IL-10) was not different from the control. However, the response to influenza vaccine treatment exhibited a trend whereby there was a raise in the levels of Th1 cytokines (IL-2, IFN-γ and TNF-α) at 7 days followed by a progessive drop and return to base line, while the Th2 cytokines (IL-4 and IL-10) exhbited a downward trend without return to base line. Figure 2 shows that treatment with cyclosporine lead to a reduction in the levels of Th1 cytokines (IL-2, IFN-γ and TNF-α), and this was statistically significant for IL-2 at 7 days of treatment (P = 0.0357). Regarding Th2 cytokines, cyclosporine lead to a sharp raise in IL-10 at 7 days after which it returnred to baseline at 14 days of treatment. The corresponding concentrations of cyclosporine were 38 (38-42) ng/ml after 7 days and 88 (38 -116) ng/ml after 14 days of treatment. Figure 3 shows that the effect of treatment with PHELA on Th1 cytokines (IL-2, IFN-γ and TNF-α) and Th2 cytokines (IL-4 and IL-10) was not different from the control. However, the response to PHELA exhibited a trend whereby there was a raise in the Th2 cytokines levels (IL-4 and IL-10) at 7 days followed by a progressive drop and return to base line. While the TH1 cytokines exhibited an upward trend without return to base line.
Influenza vaccine
Cyclosporine
PHELA
PHELA + Cyclosporine
In Figure 4 , co-administration PHELA and cyclosporine lead to a reversal of the effects of cyclosporine, i.e., increased levels of Th1 cytokines (IL-2, IFN-γ and TNF-α) versus reduced levels of Th2 cytokines (IL-4 and IL-10) at 7 days. Owing to wide variations, only the raise in IL-2 was statistically significant (p = 0.0357). The corresponding concentrations of cyclosporine were 66 (52-160) ng/ml after 7 days and 68 (48 -76) ng/ml after 14 days of treatment. There was a significant difference between the concentrations cyclosporine only group versus those with PHELA+cyclosporine (P = 0.0167) but this was observed by 14 days of treatment (P = 0.2667).
Discussion
Mechanism of action
As indicated earlier, the cytokine profile determines the type of immune response to any antigen. IIncreased Th1 cytokines lead to CMI, while increased Th2 cytokines leads to humoral immunity. In the case of viral infection, the CMI is effective in mediating removal of virus-infected cells, while the Th2 cytokines mediate production of antibodies to defend against viral invasion. However, the two cytokines must co-exist because they regulate each other regarding their actions whereby Th1 cytokines are pro-inflammatory while the Th2 are antiinflammatory, and in their production where some Th1 cytokines inhibit/stimulate release of specific Th2 cytokines and the vice versa.
Nevertheless, it is suffice to say that traditional medicines that increase Th1 cytokines would be the ideal candidates for development as immune boosters against established viral infections, while those that stimulate Th2 cytokines would be ideal for preventing viral infections. But, in this study, it has been demonstrated that PHELA acts on the immune system whereby it increased, al beit not statstically significant, the Th2 cytokines of a normal immune system at 7 days of treatment and increased or boosted the Th1 cytokines against cyclosporine induced immune suppression. Boosting in this case refers to the fact that the response to phale+cyclosporine treatment, particularly by IL-2, was higher than in the control and PHELA-only groups. This implies that PHELA has a dual action on cytokines in that it stimulates the relevant cytokines depending on the situation. The mild-moderate stimulation of Th2 cytokines of a normal immune system was probably to inhibit Th1 cytokine production and limit inflammation which was successfully achieved, while stimulation of Th1 cytokines when they were suppressed by cyclosporine was most appropriate action for the situation. Furthermore, this also implies that PHELA's actions on Th1 cytokines are more pronounced on a suppressed than on a normal immune system, which rhymes with the clinical observations studies where PHELA lead to improvement of immune markers in patients with a compromised immune system (Matsabisa G 
Interaction with cyclosporine
The interaction between PHELA and cyclosporine is unlikely to be a pharmacokinetic interaction as the concentrations of cylosporine were not different in the two groups, i.e., cyclosporine group vs. phale+cyclosporine group. The difference in concentrations of cylosporine after 7 days of treatment was most probably due to delayed absorption from the subcutaneous injection site in the cyclosporine only group. Also, preliminary studies in our laboratory in which the effect of PHELA on the activity of each the five major human drug metabolizing cytochrome P450 isoforms (CYP2D6, CYP3A4, CYP1A2, CYP2C19, and CYP2C9) were studied, showed that PHELA had no significant effect on the activity of any of these iso-enzymes, especially CYP3A. CYP3A is the enzyme responsible for cyclosporine metabolism. Furthermore, treatment of rats with PHELA at the same dose used here for 3 and 7 days had no effect on the activity of rat CYP3A and other enzymes, and this was confirmed by quantification of CYP3A by SDS-PAGE and Western Blot method. Therefore, the mechanism by which PHELA interacted with cyclosporine is not clear.
PHELA also antagonized the effect of cyclosporine on platelets. Cyclosporine is known to cause thrombotic thrombocytopenic purpura due to its activation of platelet aggregation (Lian, 1980; Grace et al, 1987; Phadke and Bagirath, 2004 ) and depletion of prostacyclin-stimulating factor (Neild et al, 1983; Leithner et al, 1982) . Unfortunately, this study did not evaluate for these factors, hence, the mechanism by which PHELA prevented the cyclosporine induced thrombocytopenia is not known.
On the other hand, since PHELA alone had no effect on the Th1 cytokines, one might say that cyclosporine augmented the action of PHELA, but this remains to be confirmed. In the same perspective, the effects of PHELA could be considered as not different from a dietary supplement which can aid restoration of a pathological situation with no further effect on a normal immune system. Well then, the latter calls for a review of the dietary recommendations in immune compromised patients because some foods such as PHELA would be more relevant than others.
Lastly, the findings of this study are also important in the chemotherapy for transplant patients, as they high lighted a potential adverse interaction between PHELA and cyclosporine that can lead to graft rejection. Therefore, transplant patients using cyclosporine should not use PHELA products.
Optimum Time to evaluate cytokine response
It was observed that cytokine profiles varied with the time lapse since administration of the drugs. For instance, except in a few cases, the response at 7 days was always reversed or weaker by 14 th day of treatment. This was most probably because the immune system countered the disruption of the respective immune mediators. It could also account for the failure by PHELA to stimulate a normal immune system but it was not clear whether the response to PHELA would be more remarkable beyond 14 days. Nevertheless, this study has demonstrated that the time period since administration of the test antigen is important for interpretation of cytokine response to antigens. It was therefore appropriate in this study to use the response at 7 days as more relevant than at 14 days even though both occasions were considered in the analysis.
Positive and negative controls
Since most studies on cytokine are characterized by wide variations in cytokine response that make, not only interpretation of data very difficult, but also cast doubt on the robustness of the experimental methods used, it was decided to include the positive and negative controls using drugs which immune response is well characterized, i.e., influenza vaccine and cyclosporine, respectively. The conviction was that if the experiment can reproduce the expected response by the two drugs, it would confirm the observations in all other groups as robust.
Regarding the response to influenza vaccine, wide variation in cytokine response to the different Influenza vaccines has been reported (Tsai et Mitchell and Callard, 1983) . Also, the response by Th1 cytokines was stronger with whole virus vaccine than with subunit vaccines (McElhaney et al, 1995; Saurwein-Teiss et al, 1998 ). In the current study, Influvacc 2009 is a trivalent subunit vaccine which, as expected, induced a mild increase in the Th1 cytokines on day 14 and moderate increase in the Th2 cytokines at day 7. Even then, our follow up was for only 21 days, yet it was observed in humans that increase in cytokines after Influenza vaccination may reach maximum between 3 and 12 weeks (McElhaney et al, 1995) . As such, it is likely that Th1 cytokines could have been higher after 21 days. Unfortunately, since the age corresponding to 12 weeks in rats is not known, monitoring rats for 12 weeks could not be done because the effects of aging may influence response to the influenza vaccine (Krakauer and Russo, 2001; McElhaney et al, 1995; Mcelhaney et al, 2002; Mcelhaney et al, 1998; McElhaney et al, 1992; ). In conclusion, in this study, the response to influvaac 2009 was as expected; a mild effect on Th1 cytokines and moderate suppression of Th2 cytokines, and this imparted a CMI (Mcelhaney et al, 1998 ). 
Phl + Cys cys
Regarding cyclosporine, the current study, like in other studies elsewhere, demonstrated that cyclosporine inhibits production of Th1 cytokines (Il-2, TNF-ά, IFN-γ) while increasing production of IL-10 with minimal or no effect on IL-4 ( . Therefore, in spite of the wide variations that might have led to lack of statistically significant differences, the observations on the effects of PHELA on the immune system are accurate. In fact, the effect of cyclosporine on cytokines, especially IL-10, was suggested to be at transcriptional level because cyclosporine increased the IL-10 mRNA (Cho et al, 2002) . It is therefore most probable that PHELA interacts with cyclosporine at transcriptions level, but this too remains to be confirmed.
In conclusion, using a rat model, it has been demonstrated that PHELA is an immune stimulant that antagonizes the effects of cyclosporine with minimal effect on a normal immune system in first 14 days of treatment. This implies that PHELA is an ideal candidate for further evaluation and development into an immune booster medication.
